<?xml version="1.0" encoding="UTF-8"?>
 <!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
 <article article-type="research-article" dtd-version="3.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
   <journal-meta>
    <journal-id journal-id-type="publisher-id">SM</journal-id>
    <journal-title-group>
     <journal-title>Salud Mental</journal-title>
     <abbrev-journal-title>sm</abbrev-journal-title>
    </journal-title-group>
    <issn pub-type="epub">0185-3325</issn>
    <publisher>
     <publisher-name>Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz</publisher-name>
    </publisher>
   </journal-meta>
   <article-meta>
    <article-id pub-id-type="publisher-id">SM4506</article-id>
    <article-id pub-id-type="doi">SM.0185-3325.2017.033</article-id>
    <article-categories>
     <subj-group subj-group-type="heading">
      <subject>Original article</subject>
     </subj-group>
    </article-categories>
    <title-group>
     <article-title>Dual disorders in individuals under treatment for both alcohol and cocaine: Madrid study on the prevalence of dual disorders</article-title>
     <trans-title-group xml:lang="es">
      <trans-title>Patología dual en individuos en tratamiento por uso de cocaína y alcohol: estudio Madrid sobre prevalencia de patología dual</trans-title>
     </trans-title-group>
     <alt-title alt-title-type="running-head">Dual disorders in individuals under treatment for both alcohol and cocaine: Madrid study on the prevalence of dual disorders</alt-title>
    </title-group>
    <contrib-group>
     <contrib contrib-type="author">
      <name>
       <surname>José Luis</surname>
       <given-names>Palomo</given-names>
      </name>
      <xref ref-type="aff" rid="AF0001">1</xref>
     </contrib>
     <contrib contrib-type="author">
      <name>
       <surname>Francisco</surname>
       <given-names>Arias</given-names>
      </name>
      <xref ref-type="aff" rid="AF001 ">1</xref>
     </contrib>
     <contrib contrib-type="author">
      <name>
       <surname>Néstor</surname>
       <given-names>Szerman</given-names>
      </name>
      <xref ref-type="aff" rid="AF0002">2</xref>
     </contrib>
     <contrib contrib-type="author">
      <name>
       <surname>Pablo</surname>
       <given-names>Vega,</given-names>
      </name>
      <xref ref-type="aff" rid="AF0003">3</xref>
     </contrib>
     <contrib contrib-type="author">
      <name>
       <surname>Ignacio</surname>
       <given-names>Basurte</given-names>
      </name>
      <xref ref-type="aff" rid="AF0002">2</xref>
     </contrib>
     <contrib contrib-type="author">
      <name>
       <surname>Beatriz</surname>
       <given-names>Mesías</given-names>
      </name>
      <xref ref-type="aff" rid="AF0003">3</xref>
     </contrib>
    </contrib-group>
    <aff id="AF0001">
     <label>1</label>
     Servicio de Psiquiatría, Hospital Doce de Octubre, Madrid, España.
    </aff>
    <aff id="AF0002">
     <label>2</label>
     Servicio de Psiquiatría, Hospital General Gregorio Marañón, Madrid, España.
    </aff>
    <aff id="AF0003">
     <label>3</label>
     Instituto de Adicciones, Madrid, España.
    </aff>
    <author-notes>
     <corresp id="cor1">
      Correspondence: José Luis Palomo Ruiz Servicio de Psiquiatría, Hospital 12 de Octubre. Avenida de Andalucía S/N, 28041, Madrid, España. Phone: 91 390 - 8000 Email: farias1012@gmail.com
      <email xlink:href="farias1012@gmail.com">farias1012@gmail.com</email>
     </corresp>
    </author-notes>
    <pub-date pub-type="epub-ppub">
     <month>12</month>
     <year>2017</year>
    </pub-date>
    <volume>40</volume>
    <issue>6</issue>
    <fpage>257</fpage>
    <lpage>264</lpage>
    <history>
     <date date-type="received">
      <day>04</day>
      <month>04</month>
      <year>2017</year>
     </date>
     <date date-type="accepted">
      <day>17</day>
      <month>10</month>
      <year>2017</year>
     </date>
     <date date-type="Publicado on-line">
      <day>12</day>
      <month>12</month>
      <year>2017</year>
     </date>
    </history>
    <permissions>
     <copyright-statement>© 2001-2015. Todos los Derechos Reservados a Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz</copyright-statement>
     <copyright-year>2017</copyright-year>
     <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
      <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial (by-nc) Spain 3.0 License.</license-p>
     </license>
    </permissions>
    <abstract xml:lang="en">Introduction. Descriptive data about co-occurrence of alcohol and cocaine consumption is scarce, despite its important prevalence. Dual disordes shows high prevalence in clinical samples, and patients report worse evolution and need more health services. Objective. To compare psychopathology in patients in treatment with lifetime alcohol and cocaine (Alc + Coc) substance use disorder (SUD) with subjects with alcohol but not cocaine (Alc) lifetime SUD and cocaine but not alcohol (Coc) SUD. Method. The sample consisted of 837 outpatients from Madrid, Spain, under treatment in substance misuse or mental health units. Two analyses were made: we compared subjects in the Alc + Coc (n = 366) to the Alc group (n = 162), and then to the Coc group (n = 122). Socio-demographic variables were addressed by interview. The Mini International Neuropsychiatric Interview (MINI) was used to evaluate Axis I disorders and the Personality Disorder Questionnaire (PDQ) to evaluate Personality Disorders (PD). Results. Compared to Alc group, patients in the Alc + Coc group were younger, had different socio-demographic characteristics, had more proportion of cannabis and opioid SUD, had less proportion of major depressive disorder, obsessive and depressive PD, more proportion of antisocial PD and lower suicide risk. Compared to the Coc group, they had more cannabis SUD and lower opioid SUD, showed higher prevalence of bipolar disorder, general anxiety disorder, paranoid, histrionic and dependent PD. Discussion and conclusion. We present a cross-sectional study describing comorbidity of dual disordes on treatment-seeking concurrent alcohol and cocaine problematic users. This concurrence showed different dual disordes prevalence profile than single users in some specific mental disorders.</abstract>
    <trans-abstract xml:lang="es">Introducci&oacute;n. La patolog&iacute;a dual presenta una alta prevalencia en muestras cl&iacute;nicas. Estos pacientes sufren mayor comorbilidad y requieren m&aacute;s servicios. Existen escasos datos de comorbilidad por alcohol y coca&iacute;na. Objetivo. Valorar datos sociodemogr&aacute;ficos, prevalencias de trastorno por uso de sustancias (TUS), trastorno mental y trastornos de personalidad en pacientes con trastorno por uso de alcohol y coca&iacute;na frente a pacientes con uno de los dos TUS. M&eacute;todo. La muestra incluy&oacute; 837 pacientes procedentes de Centros de Salud Mental y Centros de Atenci&oacute;n a Drogodependientes. Se realizaron dos an&aacute;lisis: se compar&oacute; el grupo de alcohol y coca&iacute;na (Alc + Coc, n = 366) con el grupo de alcohol (Alc, n = 162), y posteriormente con el grupo de coca&iacute;na (Coc, n = 122). Se recogieron variables sociodemogr&aacute;ficas y sobre TUS mediante entrevista, diagn&oacute;sticos de trastorno mental del eje I mediante la entrevista estructurada Mini International Neuropsychiatric Inerview (MINI) y los trastornos de personalidad mediante el Personality Disorder Questionnaire (PDQ). Resultados. Los pacientes del grupo Alc + Coc frente al grupo Alc presentaban diferencias sociodemogr&aacute;ficas significativas, mayor prevalencia de TUS asociados, riesgo m&aacute;s alto de suicidio y mayor proporci&oacute;n de trastorno antisocial de personalidad. Adem&aacute;s, ten&iacute;an menor prevalencia de trastornos depresivos. Frente al grupo Coc presentaron mayor prevalencia de trastorno por consumo de cannabis, pero menor de opioides y mayor prevalencia de trastorno bipolar, trastorno de ansiedad generalizada y trastornos de personalidad. Discusi&oacute;n y conclusi&oacute;n. Los pacientes com&oacute;rbidos para alcohol y coca&iacute;na presentaron un distinto perfil de prevalencia de algunos trastornos mentales espec&iacute;ficos.</trans-abstract>
    <kwd-group xml:lang="en">
     <kwd>Alcohol</kwd>
     <kwd>cocaine</kwd>
     <kwd>dual disorders</kwd>
     <kwd>comorbidity</kwd>
    </kwd-group>
    <kwd-group xml:lang="es">
     <kwd>Alcohol</kwd>
     <kwd>cocaína</kwd>
     <kwd>patología dual</kwd>
     <kwd>comorbilidad</kwd>
    </kwd-group>
   </article-meta>
  </front>
 </article>

